AMGN Stock Chart & Fundamental Analysis

Interactive Chart

About Amgen Inc.

Name

Amgen Inc.

CEO

Robert A. Bradway

Website

www.amgen.com

Industry

Healthcare

Year Founded

1980

Employees

31,500

Amgen Inc. develops, manufactures, and delivers human medicines as a large-cap biotechnology and biopharmaceutical company listed on NASDAQ as AMGN. Its portfolio spans inflammation, cancer and blood disorders, bone health, cardiovascular disease, kidney-related care, and neuroscience, and it generated $36.7 billion of revenue in FY2025.

Analyst Ratings

Consensus Recommendation

Buy6

Hold0

Sell2

Fundamentals & Financials

Revenue (TTM)

$38.1B

Net Income (TTM)

$8.7B

EPS (TTM)

$16.22

ROA (TTM)

9.14%

Current Ratio

1.37

Dividend Yield

0.7%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q2 FY2026	Q1 FY2026	Q4 FY2025
Revenue	$10,054M	$8,618M	$9,896M
Cost of Sales	$2,811M	$2,744M	$1,790M
Gross Profit	$7,243M	$5,874M	$8,106M
Operating Income	$3,514M	$2,666M	$3,942M
Net Income	$2,375M	$1,819M	$1,333M
EPS	$4.4	$3.37	$2.47

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Amgen Inc.'s Technical Indicators Summary

AMGN displays a bullish technical backdrop characterized by strong trend strength and widespread buy signals across moving averages, while some oscillators read overbought. The ADX denotes a strong trend, price trades well above short- and long-term averages and the classic pivot, and on-balance volume indicates robust accumulation, supporting trend sustainability. Momentum and MACD are decisively positive even as RSI and stochastics register overbought levels, and ATR shows moderate volatility. Technical takeaway: strong buy, with broad trend and volume support outweighing short-term overbought readings.

Buy

6 signals

Neutral

0 signals

Sell

2 signals

Overall: Bullish75% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	74.32	Sell	RSI (74.32) > 70, indicating overbought conditions.
Stochastic %K (14, 3, 3)	92.09	Sell	Stochastic (92.09) > 80, indicating overbought.
CCI (20)	109.50	—	CCI (109.50) > 100, indicating strong upward momentum.
WPR (14)	-4.10	—	Williams %R (-4.10) > -20, indicating overbought.
Momentum (10)	35.26	—	Momentum (35.26) is positive.
MFI	63.60	—	MFI (63.60) is neutral.
MACD Level (12, 26)	14.79	Buy	Confirmed uptrend: MACD (14.79) is positive and above its signal line (13.28).
Bollinger Bands	$360.57 - $435.56	—	Price is within the bands.
ATR (14)	$10.41 (2.45%)	—	Moderate Volatility (2.45%).
ADX (14)	40.59	—	Strong uptrend (ADX > 25) with bullish directional movement. ADX(40.59), +DI(35.44), -DI(10.85)
OBV	73,167,700	—	Bullish volume pressure: OBV is above its 20-day SMA. OBV(73,167,700), 20D-SMA-OBV(63,383,897)
Classic Pivot Point	$416.46	—	Price ($425.28) has broken above resistance R1 ($422.52) — bullish breakout potential.
Fibonacci Pivot Point	$416.46	—	Price ($425.28) has broken above resistance R1 ($419.97) — bullish breakout potential.
Exponential Moving Averages	$347.82 - $412.70(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.
Simple Moving Averages	$350.69 - $414.90(5 indicators)	—	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the close, AMGN held onto a small 1.41% gain versus yesterday. Into the bell, a soft sector rise of 1.59% left a constructive backdrop for AMGN. BMO maintains AMGN Buy rating with a $450 target, reinforcing upside.

Trading Volume

Below 10d avg (2.6M)

2.4M

vs S&P 500 Today

Outperforming Market

+2.01%

52-Week Position

Near highs

98.7%

Updated: August 18, 2026 at 20:33 UTC